The $100 Club - Did You Get in Early on the Triple-Digit Surge of ABVX, NUTX, BLTE…?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Should l Buy ABVX?
Source: NASDAQ.COM
ABIVAX Société Anonyme: The biotechnology company reached the $100 mark on October 30, 2025, driven by its lead drug candidate, Obefazimod, which is in a pivotal phase III trial for ulcerative colitis. The stock rose from $7.83 in July 2025 to an all-time high of $138.49 in December 2025.
Nutex Health Inc.: This healthcare services company crossed the $100 threshold on April 9, 2025, reflecting significant revenue growth and profitability, with total revenue of $723.6 million for the first nine months of 2025. The stock increased from $33.56 in November 2024 to a peak of $193 in December 2025.
Cidara Therapeutics Inc.: Cidara reached the $100 milestone on October 1, 2025, following its agreement to be acquired by Merck for $221.50 per share. The stock price rose from $18.98 in November 2024, highlighting its growth potential in preventive influenza therapy.
Palvella Therapeutics Inc.: The company, focused on rare diseases, hit the $100 mark on November 24, 2025, after announcing positive results from its phase 2 study. The stock climbed from $25 in March 2025 to a peak of $112 in December 2025, reflecting investor confidence in its ongoing trials.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABVX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 126.540
Low
131.00
Averages
150.71
High
175.00
Current: 126.540
Low
131.00
Averages
150.71
High
175.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abivax Announces Royalty Certificate Buyback and $45 Million ADS Offering
- Capital Structure Simplification: Abivax SA announced the buyback of all royalty certificates issued in September 2022 for a total of $90 million, with $45 million paid in cash and the remainder as an interest-free vendor loan, aimed at simplifying its capital structure and reducing legacy obligations.
- Financing Plan: The company plans to enhance financial flexibility through a $45 million American Depositary Shares (ADS) offering, expected to close on May 7, 2026, with all repurchased royalty certificates canceled immediately after the transaction.
- Shareholder Impact: The transaction is expected to result in approximately 0.5% dilution for existing shareholders, with a 1% shareholder prior to the transaction expected to hold 0.99% afterward, reflecting the company's commitment to maintaining shareholder value.
- Strong Financial Position: As of December 31, 2025, Abivax reported €530.4 million in cash and short-term investments, providing a projected cash runway into Q4 2027, ensuring financial stability as the company advances its late-stage pipeline.
See More
Abivax Announces Royalty Certificate Repurchase and $45M ADS Offering
- Royalty Certificate Repurchase: Abivax has executed a purchase agreement to repurchase royalty certificates for $90 million, with $45 million to be paid in cash on the expected closing date of May 7, 2026, while the remaining $45 million will be offset against the issuance of ADS, thereby simplifying the capital structure and enhancing financial flexibility.
- ADS Offering Pricing: The offering of 403,347 ordinary shares is priced at $111.57 per share, based on the volume-weighted average trading price over the preceding five trading days, which will support the company's future commercialization efforts.
- Cash Position Forecast: As of December 31, 2025, Abivax reported cash and short-term investments totaling €530.4 million, projecting a cash runway into Q4 2027, ensuring funding for clinical programs and pre-commercial planning activities.
- Shareholder Dilution Impact: The issuance will result in approximately 0.5% dilution of the company's share capital, meaning a shareholder with 1% ownership before the offering will hold about 0.99% afterward, reflecting a cautious approach to capital structure adjustment.
See More
Abivax Stock Potential and Risks Analysis
- Drug Development Progress: Abivax is developing obefazimod as a potential treatment for ulcerative colitis, which regulates inflammation by increasing microRNA-124 levels, showcasing a differentiated mechanism that could lead to commercial success in the market.
- Clinical Trial Results: In an 8-week phase 3 study, obefazimod achieved significant remission in patients with moderate-to-severe ulcerative colitis, with 47.3% of patients having inadequate responses to prior therapies, highlighting the drug's potential.
- Market Outlook and Risks: Abivax's market cap stands at approximately €8.15 billion ($9.41 billion), which is relatively high for a biotech firm without a marketed product, reflecting obefazimod's potential but also indicating that any clinical or regulatory setbacks could lead to a significant stock price decline.
- Investor Decision Considerations: While Abivax's stock presents an attractive opportunity, particularly for investors with higher risk tolerance, its status as a clinical-stage company with ongoing losses suggests that investors should proceed with caution and may prefer other safer biotech firms.
See More
Abivax's Promising Drug Candidate Faces Risks Amid Market Volatility
- Clinical Trial Progress: Abivax's candidate drug obefazimod demonstrated significant potential in a phase 3 study, with 47.3% of patients showing inadequate responses to prior therapies, indicating that positive results from the upcoming maintenance study could lead to a substantial increase in the company's stock price.
- Market Volatility Impact: Despite Abivax's market cap of €8.15 billion (approximately $9.41 billion), its stock has declined by 11% since the beginning of the year, reflecting cautious market sentiment regarding its clinical progress while also presenting an opportunity for investors to buy on the dip.
- Innovative Drug Mechanism: Obefazimod operates by increasing levels of microRNA-124 to regulate inflammatory responses, differing from existing immunosuppressants, which may reduce patients' susceptibility to other diseases, thus creating a competitive edge in the market for new therapies.
- Investment Risk Assessment: As a clinical-stage biotech firm with no products on the market, Abivax presents high risks, and investors should carefully evaluate their risk tolerance before making decisions, considering that potential clinical or regulatory setbacks could lead to significant stock price fluctuations.
See More
Investment Outlook for Healthcare Stocks
- Moderna's mRNA Platform: Moderna's mRNA vaccines are favored for their rapid production and strong immune responses, particularly with its flu vaccine seeking U.S. approval, which is expected to enhance market competitiveness and drive future growth.
- Personalized Cancer Vaccine Progress: The mRNA-4157, developed in partnership with Merck, shows promising results in significantly reducing recurrence or death risk in advanced melanoma patients, with five-year follow-up data indicating optimistic clinical prospects that could sustain stock price growth over the next five years.
- Abivax's Innovative Drug: Abivax's obefazimod demonstrates excellent efficacy in treating ulcerative colitis, with clinical trials showing that 47.3% of patients previously unresponsive to traditional treatments could benefit, positioning the company to challenge market giants and achieve sales growth if approved.
- Market Competition and Risks: While Abivax faces fierce competition from large pharmaceutical companies, the unique advantages of obefazimod may allow it to capture market share over the next five years; however, the risks associated with clinical trials require cautious consideration from investors.
See More
Biotech Companies Show Promising Clinical Progress
- Moderna's mRNA Platform: Moderna's mRNA vaccines are produced faster than traditional vaccines and elicit stronger immune responses, with shares up 73% in 2023, indicating potential for continued growth over the next five years despite clinical and regulatory risks.
- Personalized Cancer Vaccine: The mRNA-4157 candidate, when combined with Keytruda, significantly reduced recurrence or death risk in advanced melanoma patients, showcasing its potential across various cancer types and likely enhancing future market performance for Moderna.
- Abivax's Innovative Drug: Abivax's obefazimod achieved its primary endpoint of clinical remission in a phase 3 trial, with 47.3% of patients previously treated unsuccessfully, positioning it as a strong competitor in the ulcerative colitis market, challenging established players if approved.
- Market Potential and Risks: If Abivax secures approval for obefazimod and expands into related conditions, its sales could soar over the next five years, but investors should remain cautious of potential clinical trial setbacks that could impact stock performance.
See More
Abivax Announces Royalty Certificate Buyback and $45 Million ADS Offering
- Capital Structure Simplification: Abivax SA announced the buyback of all royalty certificates issued in September 2022 for a total of $90 million, with $45 million paid in cash and the remainder as an interest-free vendor loan, aimed at simplifying its capital structure and reducing legacy obligations.
- Financing Plan: The company plans to enhance financial flexibility through a $45 million American Depositary Shares (ADS) offering, expected to close on May 7, 2026, with all repurchased royalty certificates canceled immediately after the transaction.
- Shareholder Impact: The transaction is expected to result in approximately 0.5% dilution for existing shareholders, with a 1% shareholder prior to the transaction expected to hold 0.99% afterward, reflecting the company's commitment to maintaining shareholder value.
- Strong Financial Position: As of December 31, 2025, Abivax reported €530.4 million in cash and short-term investments, providing a projected cash runway into Q4 2027, ensuring financial stability as the company advances its late-stage pipeline.
See More
Abivax Announces Royalty Certificate Repurchase and $45M ADS Offering
- Royalty Certificate Repurchase: Abivax has executed a purchase agreement to repurchase royalty certificates for $90 million, with $45 million to be paid in cash on the expected closing date of May 7, 2026, while the remaining $45 million will be offset against the issuance of ADS, thereby simplifying the capital structure and enhancing financial flexibility.
- ADS Offering Pricing: The offering of 403,347 ordinary shares is priced at $111.57 per share, based on the volume-weighted average trading price over the preceding five trading days, which will support the company's future commercialization efforts.
- Cash Position Forecast: As of December 31, 2025, Abivax reported cash and short-term investments totaling €530.4 million, projecting a cash runway into Q4 2027, ensuring funding for clinical programs and pre-commercial planning activities.
- Shareholder Dilution Impact: The issuance will result in approximately 0.5% dilution of the company's share capital, meaning a shareholder with 1% ownership before the offering will hold about 0.99% afterward, reflecting a cautious approach to capital structure adjustment.
See More
Abivax Stock Potential and Risks Analysis
- Drug Development Progress: Abivax is developing obefazimod as a potential treatment for ulcerative colitis, which regulates inflammation by increasing microRNA-124 levels, showcasing a differentiated mechanism that could lead to commercial success in the market.
- Clinical Trial Results: In an 8-week phase 3 study, obefazimod achieved significant remission in patients with moderate-to-severe ulcerative colitis, with 47.3% of patients having inadequate responses to prior therapies, highlighting the drug's potential.
- Market Outlook and Risks: Abivax's market cap stands at approximately €8.15 billion ($9.41 billion), which is relatively high for a biotech firm without a marketed product, reflecting obefazimod's potential but also indicating that any clinical or regulatory setbacks could lead to a significant stock price decline.
- Investor Decision Considerations: While Abivax's stock presents an attractive opportunity, particularly for investors with higher risk tolerance, its status as a clinical-stage company with ongoing losses suggests that investors should proceed with caution and may prefer other safer biotech firms.
See More
Abivax's Promising Drug Candidate Faces Risks Amid Market Volatility
- Clinical Trial Progress: Abivax's candidate drug obefazimod demonstrated significant potential in a phase 3 study, with 47.3% of patients showing inadequate responses to prior therapies, indicating that positive results from the upcoming maintenance study could lead to a substantial increase in the company's stock price.
- Market Volatility Impact: Despite Abivax's market cap of €8.15 billion (approximately $9.41 billion), its stock has declined by 11% since the beginning of the year, reflecting cautious market sentiment regarding its clinical progress while also presenting an opportunity for investors to buy on the dip.
- Innovative Drug Mechanism: Obefazimod operates by increasing levels of microRNA-124 to regulate inflammatory responses, differing from existing immunosuppressants, which may reduce patients' susceptibility to other diseases, thus creating a competitive edge in the market for new therapies.
- Investment Risk Assessment: As a clinical-stage biotech firm with no products on the market, Abivax presents high risks, and investors should carefully evaluate their risk tolerance before making decisions, considering that potential clinical or regulatory setbacks could lead to significant stock price fluctuations.
See More
Investment Outlook for Healthcare Stocks
- Moderna's mRNA Platform: Moderna's mRNA vaccines are favored for their rapid production and strong immune responses, particularly with its flu vaccine seeking U.S. approval, which is expected to enhance market competitiveness and drive future growth.
- Personalized Cancer Vaccine Progress: The mRNA-4157, developed in partnership with Merck, shows promising results in significantly reducing recurrence or death risk in advanced melanoma patients, with five-year follow-up data indicating optimistic clinical prospects that could sustain stock price growth over the next five years.
- Abivax's Innovative Drug: Abivax's obefazimod demonstrates excellent efficacy in treating ulcerative colitis, with clinical trials showing that 47.3% of patients previously unresponsive to traditional treatments could benefit, positioning the company to challenge market giants and achieve sales growth if approved.
- Market Competition and Risks: While Abivax faces fierce competition from large pharmaceutical companies, the unique advantages of obefazimod may allow it to capture market share over the next five years; however, the risks associated with clinical trials require cautious consideration from investors.
See More
Biotech Companies Show Promising Clinical Progress
- Moderna's mRNA Platform: Moderna's mRNA vaccines are produced faster than traditional vaccines and elicit stronger immune responses, with shares up 73% in 2023, indicating potential for continued growth over the next five years despite clinical and regulatory risks.
- Personalized Cancer Vaccine: The mRNA-4157 candidate, when combined with Keytruda, significantly reduced recurrence or death risk in advanced melanoma patients, showcasing its potential across various cancer types and likely enhancing future market performance for Moderna.
- Abivax's Innovative Drug: Abivax's obefazimod achieved its primary endpoint of clinical remission in a phase 3 trial, with 47.3% of patients previously treated unsuccessfully, positioning it as a strong competitor in the ulcerative colitis market, challenging established players if approved.
- Market Potential and Risks: If Abivax secures approval for obefazimod and expands into related conditions, its sales could soar over the next five years, but investors should remain cautious of potential clinical trial setbacks that could impact stock performance.
See More
